vorasidenib

Also Known As:

1,3,5-Triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-N2,N4-bis((1R)-2,2,2-trifluoro-1-methylethyl)-; 6-(6-Chloro-2-pyridinyl)-N,N'-bis((2R)-1,1,1-trifluoro-2-propanyl)-1,3,5-triazine-2,4-diamine

Networked: 14 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Polyamines: 3918
    - Diamines: 518
      - vorasidenib: 14
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - vorasidenib: 14

Experts

1.	Mellinghoff, Ingo K: 2 articles (01/2021 - 02/2020)
2.	Agoni, Clement: 1 article (05/2021)
3.	Poonan, Preantha: 1 article (05/2021)
4.	Soliman, Mahmoud E S: 1 article (05/2021)
5.	Burris, Howard A: 1 article (01/2021)
6.	Choe, Sung: 1 article (01/2021)
7.	Chun, Saewon: 1 article (01/2021)
8.	Clarke, Jennifer L: 1 article (01/2021)
9.	Cloughesy, Timothy F: 1 article (01/2021)
10.	Cote, Gregory M: 1 article (01/2021)

Related Diseases

1.	Glioma (Gliomas) 08/17/2023 - "In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention. " 11/20/2023 - "[Vorasidenib for low-grade gliomas-new treatment option with unanswered questions regarding long-term outcomes]." 08/17/2023 - "In a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles. " 01/01/2021 - "Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial." 08/17/2023 - "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma."
2.	Disease Progression 08/17/2023 - "Progression-free survival was significantly improved in the vorasidenib group as compared with the placebo group (median progression-free survival, 27.7 months vs. 11.1 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.27 to 0.56; P<0.001). " 08/17/2023 - "Crossover to vorasidenib from placebo was permitted on confirmation of imaging-based disease progression. "
3.	Neoplasms (Cancer) 01/01/2023 - "Tumor 2-HG concentrations were reduced by 92.6% (95% credible interval (CrI), 76.1-97.6) and 91.1% (95% CrI, 72.0-97.0) in patients treated with vorasidenib 50 mg q.d. " 01/01/2021 - "We conducted a multicenter, open-label, phase I, dose-escalation study of vorasidenib in 93 patients with mutant IDH1/2 (mIDH1/2) solid tumors, including 52 patients with glioma that had recurred or progressed following standard therapy. " 01/01/2023 - "Primary end-point was concentration of D-2-hydroxyglutarate (2-HG), the metabolic product of mIDH enzymes, measured in tumor tissue from 49 patients with mIDH1-R132H nonenhancing gliomas following randomized treatment with vorasidenib (50 mg or 10 mg once daily, q.d.), ivosidenib (500 mg q.d. "
4.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2023 - "Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study."
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/01/2019 - "Isocitrate dehydrogenase (IDH) inhibitors comprise a novel class of anticancer drugs, which are approved to treat acute myeloid leukemia patients having mutations on IDH1/2. We report the development and validation of a high-performance liquid chromatography (HPLC) method for the simultaneous quantitation of IDH inhibitors, namely enasidenib (EDB), ivosidenib (IDB) and vorasidenib (VDB), in mouse plasma as per the US Food and Drug Administration regulatory guidelines. "

Related Drugs and Biologics

1.	Indigo Carmine (Indigo Blue)
2.	ivosidenib
3.	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))
4.	Enzymes
5.	dabrafenib
6.	trametinib
7.	alpha-hydroxyglutarate
8.	enasidenib

Related Therapies and Procedures

1.	Chemoradiotherapy
2.	Therapeutics